samedan logo

 
 
spacer
home > ebr > spring 2003 > maldi-tof - the technique of choice in proteomics
PUBLICATIONS
European Biopharmaceutical Review

MALDI-TOF - The Technique of Choice in Proteomics

Mass spectrometry is now widely viewed as the analytical technique of choice in proteomics. Its popularity has been driven by the high degree of sensitivity it offers and the ability to search data against rapidly expanding protein and expressed sequence tag (EST) databases. The procedure is based on the generation of gaseous ions from analyte molecules, the subsequent separation of these ions according to their mass to charge (m/z) ratio and the detection of these ions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Chris Sutton, Global Business Manager with Kratos Analytical

Dr Chris Sutton is Global Business Manager for MALDI mass spectrometers with Kratos Analytical, part of Shimadzu Biotech. Shimadzu Biotech, a subsidiary of Shimadzu Corporation, is one of the key providers of analytical solutions for life science and drug discovery.

Chris holds global responsibility for MALDI MS business including sales and marketing, applications, engineering and research and development. He is based at the Kratos Analytical facility in Manchester, UK.

spacer
Dr Chris Sutton
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo maintains its steady growth.

According to the data obtained by WACD, the international air cargo information provider, in May; Turkish Cargo, the global air cargo brand providing service to 124 countries around the world, increased its tonnage rate by 7.1 percent, and grew substantially across the industry which shrank by 5.1 percent in the global air cargo market.
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement